BFM
CTIC

Boothbay Fund Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Boothbay Fund Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-106,949
Closed -$643K – 2734
2022
Q4 		$643K Buy
+106,949
New +$584K 0.01% 1072
2021
Q1 		– Sell
-39,106
Closed -$126K – 2016
2020
Q4 		$126K Buy
+39,106
New +$130K ﹤0.01% 1162

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Boothbay Fund Management's CTIC Position: Q1 2023 in Review

Boothbay Fund Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 106,949 shares — an estimated $643K sold.

Boothbay Fund Management first reported a position in CTIC in Q4 2020 and held it in 2 quarters. The position peaked at $643K in Q4 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

  • Boothbay Fund Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 106,949 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $643K.
  • Boothbay Fund Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 2 quarters.
  • Boothbay Fund Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $643K in Q4 2022.
  • 133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.